Following a Priority Review, the US Food and Drug Administration has approved Giapreza (angiotensin II) injection for intravenous infusion to increase blood pressure (BP) in adults with septic or other distributive shock.
Giapreza was approved following a clinical trial of 321 patients with shock and dangerously low BP. Results of the trial showed that significantly more patients had responded to treatment with Giapreza vs placebo.
Patients taking Giapreza should also be treated with prophylactic blood clot treatments, since Giapreza can cause dangerous blood clots with serious consequences, including deep venous thrombosis.
FDA approves drug to treat dangerously low blood pressure [press release]. US Food and Drug Administration. December 21, 2017. https://www.fda.gov/NewsEvents/Newsroom/Press Announcemen-
ts/ucm590249.htm. Accessed December 22, 2017.